Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity.
Turner JA, Stephen-Victor E, Wang S, Rivas MN, Abdel-Gadir A, Harb H, Cui Y, Fanny M, Charbonnier LM, Fong JJH, Benamar M, Wang L, Burton OT, Bansal K, Bry L, Zhu C, Li QZ, Clement RL, Oettgen HC, Crestani E, Rachid R, Sage PT, Chatila TA. Turner JA, et al. Among authors: crestani e. Immunity. 2020 Dec 15;53(6):1202-1214.e6. doi: 10.1016/j.immuni.2020.10.002. Epub 2020 Oct 20. Immunity. 2020. PMID: 33086036 Free PMC article.
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
Bird JA, Spergel JM, Jones SM, Rachid R, Assa'ad AH, Wang J, Leonard SA, Laubach SS, Kim EH, Vickery BP, Davis BP, Heimall J, Cianferoni A, MacGinnitie AJ, Crestani E, Burks AW; ARC001 Study Group. Bird JA, et al. Among authors: crestani e. J Allergy Clin Immunol Pract. 2018 Mar-Apr;6(2):476-485.e3. doi: 10.1016/j.jaip.2017.09.016. Epub 2017 Oct 31. J Allergy Clin Immunol Pract. 2018. PMID: 29092786 Free article. Clinical Trial.
Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment.
Albuhairi S, Sare T, Lakin P, El Khoury K, Crestani E, Schneider LC, Anzaldi R, Patterson A, Rachid R. Albuhairi S, et al. Among authors: crestani e. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1711-1716.e4. doi: 10.1016/j.jaip.2017.11.040. Epub 2018 Jan 12. J Allergy Clin Immunol Pract. 2018. PMID: 29339129
Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy.
Abdel-Gadir A, Stephen-Victor E, Gerber GK, Noval Rivas M, Wang S, Harb H, Wang L, Li N, Crestani E, Spielman S, Secor W, Biehl H, DiBenedetto N, Dong X, Umetsu DT, Bry L, Rachid R, Chatila TA. Abdel-Gadir A, et al. Among authors: crestani e. Nat Med. 2019 Jul;25(7):1164-1174. doi: 10.1038/s41591-019-0461-z. Epub 2019 Jun 24. Nat Med. 2019. PMID: 31235962 Free PMC article.
Dietary and Microbial Determinants in Food Allergy.
Stephen-Victor E, Crestani E, Chatila TA. Stephen-Victor E, et al. Among authors: crestani e. Immunity. 2020 Aug 18;53(2):277-289. doi: 10.1016/j.immuni.2020.07.025. Immunity. 2020. PMID: 32814026 Free PMC article. Review.
A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma.
Harb H, Stephen-Victor E, Crestani E, Benamar M, Massoud A, Cui Y, Charbonnier LM, Arbag S, Baris S, Cunnigham A, Leyva-Castillo JM, Geha RS, Mousavi AJ, Guennewig B, Schmitz-Abe K, Sioutas C, Phipatanakul W, Chatila TA. Harb H, et al. Among authors: crestani e. Nat Immunol. 2020 Nov;21(11):1359-1370. doi: 10.1038/s41590-020-0777-3. Epub 2020 Sep 14. Nat Immunol. 2020. PMID: 32929274 Free PMC article.
Author Correction: A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma.
Harb H, Stephen-Victor E, Crestani E, Benamar M, Massoud A, Cui Y, Charbonnier LM, Arbag S, Baris S, Cunnigham A, Leyva-Castillo JM, Geha RS, Mousavi AJ, Guennewig B, Schmitz-Abe K, Sioutas C, Phipatanakul W, Chatila TA. Harb H, et al. Among authors: crestani e. Nat Immunol. 2021 Jan;22(1):100. doi: 10.1038/s41590-020-00841-w. Nat Immunol. 2021. PMID: 33214720 No abstract available.
Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.
Phipatanakul W, Mauger DT, Guilbert TW, Bacharier LB, Durrani S, Jackson DJ, Martinez FD, Fitzpatrick AM, Cunningham A, Kunselman S, Wheatley LM, Bauer C, Davis CM, Geng B, Kloepfer KM, Lapin C, Liu AH, Pongracic JA, Teach SJ, Chmiel J, Gaffin JM, Greenhawt M, Gupta MR, Lai PS, Lemanske RF, Morgan WJ, Sheehan WJ, Stokes J, Thorne PS, Oettgen HC, Israel E; PARK Study Team. Phipatanakul W, et al. Contemp Clin Trials. 2021 Jan;100:106228. doi: 10.1016/j.cct.2020.106228. Epub 2020 Nov 24. Contemp Clin Trials. 2021. PMID: 33242697 Free PMC article. Clinical Trial.
36 results